C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
State-of-the-art management of metastatic disease at initial presentation or recurrence
Fabio Calabrò,Cora N. Sternberg +1 more
TL;DR: Since cisplatin-containing regimens are contraindicated for patients with impaired renal function, gemcitabine plus either paclitaxel or docetaxel may be an effective and well-tolerated treatment option for these patients.
Journal ArticleDOI
Recombinant tumor necrosis factor for superficial bladder tumors.
Cora N. Sternberg,M. G. Arena,Vito Pansadoro,F. Calabresi,Igea D'Agnano,P. De Carli,M. Zeuli,A. Cancrini,F. Rosenkaimer,Gabriella Zupi +9 more
TL;DR: Twenty patients with histologically documented superficial bladder cancer were treated with intravesical administration of TNF 400-1800 micrograms, and no patients developed antibodies to intravesically administered TNF.
Journal ArticleDOI
An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)
J.S. de Bono,Joaquim Bellmunt,J.P. Droz,Kurt Miller,Gerhard Zugmaier,Cora N. Sternberg,V. Gimenez,Chris Parker,Malcolm David Mason,Janet Graham +9 more
TL;DR: The primary endpoint in this study was PSA (prostate specific antigen) response rate (RR) at 24 weeks after start of single agent P.
Journal ArticleDOI
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
Roberto Iacovelli,Alessio Farcomeni,Cora N. Sternberg,Giacomo Cartenì,Michele Milella,Matteo Santoni,Linda Cerbone,Giuseppe Di Lorenzo,Elena Verzoni,Cinzia Ortega,Roberto Sabbatini,Riccardo Ricotta,Caterina Messina,Vito Lorusso,Francesco Atzori,Fabio De Vincenzo,Cosimo Sacco,Francesco Boccardo,F. Valduga,Francesco Massari,Valentina Baldazzi,Saverio Cinieri,Alessandra Mosca,Enzo Maria Ruggeri,Alfredo Berruti,Giuseppe Procopio +25 more
TL;DR: This nomogram included clinical and biochemical prognostic factors in patients with metastatic renal cell carcinoma who received a third line targeted agent and may be useful to select patients and define the prognosis in clinical trials.
Journal ArticleDOI
The role of docetaxel based therapy for prostate cancer in the era of targeted medicine
TL;DR: The increased understanding of the mechanisms of progressive castration‐resistant prostate cancer is being translated into an increasing pipeline of novel therapies and trials are attempting to build on the backbone of docetaxel by combining it with novel biological agents.